In the grand landscape of global investment and industrial development, Index Ventures, as a highly influential venture capital firm, has always shone brightly. Index Ventures has meticulously positioned itself in the Chinese healthcare market and officially established its Hong Kong subsidiary, JinYi Connect, in 2025. This move is like planting a highly promising seed in the Asian market, foreshadowing a brilliant journey for JinYi Connect in the fields of biomedicine and emerging technology industries.
Index Ventures boasts deep industry experience and a broad global network. Its past investment portfolio in the healthcare sector has been remarkably successful. Its early-stage investment in Oxford Nanopore Technologies, a UK-based gene sequencing technology company, helped it grow into a multi-billion dollar enterprise. As an early-stage investor in BioNTech, a German pioneer in mRNA vaccines, Index Ventures witnessed and propelled its significant breakthroughs in the vaccine field. It participated in multiple funding rounds for Beam Therapeutics, a US-based gene editing company focused on CRISPR technology, concentrating on rare disease treatments and contributing to the fight against medical challenges. In the internet sector, Index Ventures' investment in Asia Innovation Group is equally impressive, helping it grow from its inception into a mobile internet company with branches in multiple cities and widespread influence. This rich and successful investment experience has provided JinYi Interconnect with invaluable strategic guidance and resource support. JinYi Interconnect is able to stand on the shoulders of giants, accurately observe the development trends of the biopharmaceutical and emerging technology industries, and quickly connect with cutting-edge global technologies and high-quality project resources. In recent years, China's biopharmaceutical industry has developed rapidly. Rising economic levels, an aging population, and increased health awareness are jointly driving the continued expansion of China's healthcare market. JinYi Connect, leveraging the professional investment team at Index Ventures, delves into high-quality investment targets in China's biopharmaceutical sector. In the technology startup industry, JinYi Connect is committed to building a bridge connecting the innovation ecosystems of East and West. On one hand, it introduces advanced Western technological concepts, technologies, and business models, combining them with the needs and characteristics of the Asian market for localized innovation. For example, in the integration of artificial intelligence and medical technology, it draws on advanced technologies from Europe and the United States in areas such as medical image recognition and intelligent diagnostic algorithms, combining them with Asia's rich medical data resources and huge market demand to help innovative companies develop products and services more suitable for the local healthcare system. On the other hand, it helps Asian technology startups reach the international stage. Asia boasts numerous highly innovative startups with unique advantages in areas such as mobile healthcare and digital health management. Through close collaboration with local entrepreneurs, businesses, and government agencies, JinYi Connect provides these companies with services such as cross-cultural management consulting, international market access guidance, and expanded financing channels, helping them overcome the challenges of globalization and gain recognition in the international market.
Looking ahead, with the strong support of Index Ventures, Kinglink will continue to cultivate the biopharmaceutical and technology startup industries, constantly discovering and nurturing more globally competitive innovative companies, making significant contributions to promoting industry development, improving human health and well-being, and facilitating global scientific and technological exchange and cooperation, and becoming a shining star in the industry.
